Verordnungsfähigkeit von Insulinanaloga (G-SIG: 16051349)

This question concerns the eligibility of insulin analogues for reimbursement under statutory health insurance. It seeks clarification on the criteria and processes involved in determining which insulin analogues are covered. This impacts patients requiring insulin therapy, healthcare providers, and pharmaceutical companies. It affects access to specific diabetes treatments and the financial burden on the health system.